Login to Your Account

Other News To Note

Wednesday, August 21, 2013
• Prima Biomed Ltd., of Sydney, Australia, said the Korean Ministry of Food and Drug Safety granted approval to begin the Phase II/III CANcer VAccine Study (CANVAS) of CVac at several sites. The company expects the sites in Korea – the first in Asia – to begin recruiting in several weeks.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription